13F Holdings
中文EN

CTMX CytomX Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1501989 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-87.7%
TTM net income YoY-404.9%
TTM EPS YoY-329.6%
Revenue 3-yr CAGR-43.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-676.5%
Net margin-609.0%
FCF margin-363.6%
EBITDA margin—

Returns

ROE-43.6%
ROA-32.7%
ROIC (approx.)-46.3%
Asset turnover0.05x

Leverage & solvency

Liabilities / assets21.9%
Debt / equity0.00x
Current ratio7.82x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.59x
Accruals ratio-13.5%
Payout ratio—
Capex / revenue5.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$76.20M$138.10M$101.21M$53.16M$37.31M
R&D expense$68.73M$83.38M$77.68M$111.65M$114.19M
SG&A expense$29.84M$29.73M$30.02M$42.85M$39.16M
Operating income-$22.36M$25.00M-$6.48M-$101.33M-$116.04M
Pretax income-$17.13M$32.09M$3.32M-$99.32M-$115.87M
Income tax$238,000$224,000$3.89M$0$0
Net income-$17.37M$31.87M-$569,000-$99.32M-$115.87M
EBITDA-$21.16M$26.59M-$4.48M-$99.03M-$113.44M
EPS (diluted)—————
Weighted avg. shares (diluted)137.94M84.75M73.81M65.74M64.15M
Balance sheet
Cash & equivalents$12.67M$38.05M$17.17M$193.65M$205.53M
Short-term investments$124.39M$62.57M$157.34M$0$99.70M
Receivables$2.01M$3.10M$3.43M$35.99M$790,000
Current assets$143.92M$107.31M$182.94M$237.10M$310.30M
PP&E, net$1.30M$2.47M$3.96M$5.07M$5.96M
Goodwill$949,000$949,000$949,000$949,000$949,000
Total assets$151.57M$120.53M$201.79M$260.89M$339.41M
Current liabilities$46.62M$85.77M$155.91M$152.61M$77.87M
Total liabilities$52.56M$120.99M$249.24M$346.64M$339.87M
Shareholders' equity$99.01M-$456,000-$47.45M-$85.75M-$459,000
Shares outstanding170.19M80.10M67.31M66.23M65.39M
Cash flow statement
Operating cash flow-$75.59M-$86.23M-$56.03M-$110.79M-$119.03M
Capital expenditure$220,000$310,000$840,000$1.74M$1.61M
Free cash flow-$75.81M-$86.54M-$56.88M-$112.53M-$120.64M
Investing cash flow-$59.74M$99.70M-$150.67M$98.26M$22.49M
Financing cash flow$110.45M$7.52M$30.23M$648,000$110.21M
Depreciation & amortization$1.20M$1.60M$2.00M$2.30M$2.60M
Stock-based compensation$6.30M$7.67M$8.56M$13.12M$13.17M

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.